Jamie Cesanek

Articles

Abiraterone-based triplet boosts survival in de novo mCSPC

May 02, 2022

Findings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Adding abiraterone to ADT/docetaxel may be new standard in de novo mCSPC

September 20, 2021

Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel may be the new standard of care for the treatment of patients with de novo metastatic castration-sensitive prostate cancer.